Shares of Kodiak Sciences Inc. KOD dropped notably during Thursday’s trading after the company reported a larger-than-anticipated fourth-quarter loss.
Kodiak Sciences recorded a quarterly loss of $1.13 per share, exceeding market projections calling for a loss of 77 cents per share.
Kodiak Sciences shares experienced a significant decline of 19.9% to $5.97 on Thursday.
Here is a snapshot of other stocks making moves during the mid-day session today.
Winners
- Avalo Therapeutics, Inc. AVTX saw its shares surge by 430% to $25.35 after announcing the acquisition of a Phase 2-ready anti-IL-1β mAb, known as AVTX-009, through the purchase of privately held AlmataBio. The company also revealed a private placement financing of up to $185 million.
- Xilio Therapeutics, Inc. XLO climbed by 146% to $1.58 following the announcement of an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company also disclosed an $11.3 million private placement equity financing.
- Biodexa Pharmaceuticals Plc BDRX witnessed an 80% increase to $1.5395. Biodexa’s MTX110 demonstrated promising results in extending life expectancy for aggressive brain cancers.
- Ontrak, Inc. OTRK climbed 55% to $0.9239.
- Binah Capital Group, Inc. BCG rose by 48% to $14.05 after a more than 20% decline on Wednesday.
- Kidpik Corp. PIK gained 40.7% to $4.5999. Kidpik recently returned to compliance with the Nasdaq minimum bid price requirement.
- Allego N.V. ALLG rose by 32.8% to $1.7650.
- Akanda Corp. AKAN advanced by 28% to $0.2053 after unveiling plans to explore opportunities in Bitcoin, Blockchain, and AI applications within the cannabis sector.
- Destiny Tech100 Inc. DXYZ rose by 26% to $22.15.
- REX American Resources Corporation REX climbed 23.2% to $54.15 following positive earnings news.
- Nutriband Inc. NTRB gained 23% to $4.98. Nutriband recently outlined a clinical and regulatory roadmap for its AVERSA Fentanyl patch.
- Summit Therapeutics Inc. SMMT rose by 22.8% to $4.6050.
Losers
- Primech Holdings Ltd. PMEC experienced a 46.7% decline to $2.07 after providing financial updates and corporate highlights